10-Q: electroCore Q3 Sales Surge 33%, Net Loss Widens Amid Strategic Investments

electroCore reported a 33% increase in Q3 net sales to $8.7 million, driven by prescription and wellness products, but net loss widened to $3.4 million as operating expenses rose.

Summary

• Net sales for the three months ended September 30, 2025, increased 33% to $8.7 million, and for the nine months, sales rose 26% to $22.8 million, compared to the same periods in 2024.
• Gross profit increased by $2.0 million in Q3 2025 and $4.3 million for the nine months ended September 30, 2025, with gross margins at 86% for both periods.
• Net loss for Q3 2025 was $3.4 million, an increase from $2.5 million in Q3 2024, and for the nine months, net loss was $10.9 million, up from $8.7 million in the prior year.
• Operating expenses increased significantly, with selling, general and administrative expenses up 27% in Q3 and 22% for the nine months, driven by sales and marketing investments and professional fees.
• Acquired NeuroMetrix, Inc. (NURO) on May 1, 2025, integrating the Quell platform for fibromyalgia and chronic pain.
• Secured $7.5 million in Tranche 1 of a $12.0 million term loan facility with Avenue, with an option for an additional $4.5 million (Tranche 2) by December 31, 2025, subject to milestones.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $13.2 million as of September 30, 2025.
• The company's stockholders' equity was less than $2.5 million as of September 30, 2025, falling below Nasdaq's Equity Standard.
• Facing a patent and trademark infringement lawsuit from UAB Pulsetto, with electroCore asserting counterclaims.
• The ongoing U.S. federal government shutdown, which began October 1, 2025, poses a risk to sales, collections, and regulatory timelines, particularly with the VA and Air Force.

Sentiment

Score: 4

Explanation: While revenue growth is positive, the widening net losses, increased cash burn from operations, and the significant decline in stockholders' equity to a deficit, coupled with the Nasdaq listing risk and government shutdown impact, indicate substantial financial challenges and uncertainty. The capital raises provide some liquidity but also highlight ongoing funding needs.

Positives

• Net sales increased by 33% to $8.7 million for the three months ended September 30, 2025, and by 26% to $22.8 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Gross profit increased by $2.0 million in Q3 2025 and $4.3 million for the nine months ended September 30, 2025, with gross margins improving to 86% in both periods.
• Successful acquisition of NeuroMetrix, Inc. (NURO) on May 1, 2025, expanding the product portfolio with the Quell platform for fibromyalgia and chronic pain.
• Secured $7.5 million in Tranche 1 of a new $12.0 million term loan facility with Avenue, enhancing liquidity.
• Quell Fibromyalgia was launched to VA customers in May 2025 and added to the Lovell contracting platform, expanding market access.
• New gammaCore platform, Emerald, was added to the Lovell contracting platform in October 2025.
• The Rockaway, NJ lease was extended for an additional 10 years and expanded from 13,643 square feet to 22,557 square feet, providing long-term operational stability.

Negatives

• Net loss widened to $3.4 million for the three months ended September 30, 2025, from $2.5 million in the prior year, and to $10.9 million for the nine months, from $8.7 million.
• Operating expenses increased significantly, with selling, general and administrative expenses rising by $2.1 million (27%) in Q3 and $5.1 million (22%) for the nine months, outpacing revenue growth.
• Cash used in operating activities increased to $6.6 million for the nine months ended September 30, 2025, from $5.7 million in the prior year.
• Stockholders' equity was less than $2.5 million as of September 30, 2025, falling below Nasdaq's Equity Standard, posing a delisting risk.
• The company has never been profitable and expects to continue incurring net losses for the near future.
• Interest expense increased significantly to $208,000 in Q3 2025 from $5,000 in Q3 2024, and to $266,000 for the nine months from $128,000, due to new debt financing.
• Other expense of $375,000 in Q3 2025 and $714,000 for the nine months, primarily due to non-recurring acquisition-related costs and professional fees.

Risks

• Failure to meet Nasdaq's continued listing standards (specifically the Equity Standard, as stockholders' equity was less than $2.5 million as of September 30, 2025) could result in delisting, negatively impacting stock price, liquidity, and access to capital markets.
• Ongoing litigation with UAB Pulsetto regarding patent and trademark infringement could be costly, time-consuming, divert management attention, and if adversely determined, materially affect financial position and business operations.
• The ongoing U.S. federal government shutdown (began October 1, 2025) and any future lapses in appropriations could materially and adversely affect sales, collections, operations, product development, and regulatory timelines, particularly impacting sales to the VA and U.S. Air Force.
• Significant concentration of revenue from the U.S. Department of Veterans Affairs and Department of Defense (VA), which accounted for 69.9% of net sales in Q3 2025 and 70.6% for the nine months, making the company vulnerable to changes in government procurement or funding.
• Exposure to foreign currency exchange risks related to revenue and operating expenses in currencies other than the local currencies in which it operates (e.g., British Pound Sterling, Japanese Yen).
• Uncertainties and changes in global economic conditions, international trade policies, tariffs, and supply chain dynamics could influence costs, availability, or timing of materials and components.
• Risks associated with commercialization of Truvaga through e-commerce marketplaces, including inventory management, broader competition, potential account suspensions, and loss of control over brand identity and customer relationships.
• Inability to achieve or maintain profitability, which could force the company to reduce or terminate operations.
• Future capital requirements are difficult to forecast and depend on factors outside of control; inability to achieve planned operating results or maintain sufficient financial resources could materially and adversely affect the business.
• NICE review of gammaCore guidance in 2025 could adversely impact the ability to work with NHS England on the MTFM program and financial results.

Future Outlook

We expect to continue incurring net losses for the near future as we invest in sales and marketing to drive market acceptance of prescription products (gammaCore, Quell) and general wellness products (Truvaga, TAC-STIM). Research and development expenses are anticipated to be higher than comparable periods in 2024. We believe current cash, marketable securities, expected cash flow from operations, and access to capital through the ATM facility and potential Tranche 2 of the Avenue loan will fund operations for at least the next 12 months, though future capital requirements are difficult to forecast and depend on commercial success.

Management Comments

• "We intend to continue to make targeted investments in sales and marketing to continue driving commercial activities."
• "We expect that the majority of our remaining 2025 fiscal year revenue will continue to come from the prescription products sold into the VA and the Truvaga direct-to-consumer product offering."
• "For the remainder of 2025, we expect our research and development expense to be higher than the comparable periods in 2024."
• "For the remainder of 2025, we plan on continuing to make targeted investments in sales and marketing to support our commercial efforts, particularly around sales and marketing efforts across all major U.S. channels."
• "Based on our current assessment, we believe our cash, cash equivalents, restricted cash, and marketable securities, plus the net proceeds from Tranche 1 of the Term Loan, and expected cash flow from operations and access to capital through the use of the ATM pursuant to the Sales Agreement and Tranche 2 of the Term Loans will enable us to fund our operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying financial statements are issued."

Industry Context

electroCore operates in the growing bioelectronic technology and neuromodulation market, focusing on non-invasive therapies for chronic pain and headache, alongside general wellness products. The acquisition of NeuroMetrix's Quell platform strengthens its position in the chronic pain segment. The company's significant reliance on government contracts (VA, DoD) for prescription device sales highlights a specific market niche, while its direct-to-consumer Truvaga offering taps into broader wellness trends. The ongoing legal dispute with Pulsetto underscores the competitive and intellectual property-intensive nature of the bioelectronic device industry.

Legal Proceedings

• UAB Pulsetto v. electroCore, Inc.: Pulsetto filed a declaratory judgment action on June 11, 2025, asserting its nVNS product does not infringe electroCore's U.S. Patent No. 11,446,491.
• electroCore filed counterclaims on July 16, 2025, asserting Pulsetto infringes multiple U.S. Patents (Nos. 11,446,491, 8,948,873, 9,339,653, 10,874,857, 8,843,210, 9,242,092, 11,623,078, and 10,441,780) and trademarks (Truvaga, gammaCore), and committed false advertising and unfair competition.
• Pulsetto requested leave to file a motion to dismiss electroCore's counterclaims on September 5, 2025.
• A schedule for discovery and certain proceedings was approved by the court on September 9, 2025.
• The company believes Pulsetto's claim is without merit and intends to vigorously defend and pursue its counterclaims.

Related Party Transactions

• An executive of the company co-founded the Vagus Nerve Society.
• The company incurred aggregate expenses of $30,000 for the three months ended September 30, 2025, and $120,000 for the nine months ended September 30, 2025, for unrestricted and directed educational grants to the Vagus Nerve Society.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises (ATM, Shelf Registration). Risk of delisting from Nasdaq due to falling below the Equity Standard could negatively impact liquidity and market price. Widening net losses and increased cash burn could erode shareholder value.
• Employees: Increased headcount in R&D and potential for separation costs associated with headcount reductions mentioned in SG&A.
• Customers (VA/DoD): Continued strong sales to the VA, but risk of disruption from U.S. government shutdowns could affect product availability and procurement.
• Customers (General Wellness): Expansion of Truvaga and Quell offerings, but risks associated with e-commerce marketplaces could impact customer relationships and brand perception.
• Creditors (Avenue): Avenue holds a senior secured lien on substantially all company assets and a negative pledge on intellectual property, providing strong collateral for the $7.5 million loan. Avenue also has a conversion right for up to $2.5 million of the loan.
• Former NURO Shareholders: Entitled to contingent cash payments under the CVR Agreement based on Quell Net Sales and other factors, with initial distributions made in October 2025.

Next Steps

• Continue targeted investments in sales and marketing to drive commercial activities for gammaCore, Quell, Truvaga, and TAC-STIM.
• Pursue the potential $4.5 million under Tranche 2 of the Term Loans from Avenue, subject to customary conditions and achievement of certain performance milestones by December 31, 2025.
• Monitor and respond to the UAB Pulsetto litigation, vigorously defending against claims and pursuing counterclaims.
• Address Nasdaq's continued listing standards to avoid delisting, potentially by improving stockholders' equity or meeting other standards.
• Monitor and implement contingency plans for the U.S. federal government shutdown's impact on sales, collections, and regulatory processes.
• NICE to review gammaCore guidance document in 2025, which may impact the MTFM program in the UK.
• Prepare and file a registration statement on Form S-3 for the resale of Subscription Shares and shares issuable upon Avenue's Conversion Right.

Key Dates

Recommendation

While electroCore demonstrates strong revenue growth driven by its prescription and wellness products, and has secured additional financing, the widening net losses, increased cash burn from operations, and the significant decline in stockholders' equity to a deficit are concerning. The risk of Nasdaq delisting due to non-compliance with listing standards, coupled with the ongoing legal dispute and potential impacts from the U.S. government shutdown, introduce substantial uncertainty. The company's ability to fund operations for the next 12 months relies on achieving planned operating results and accessing additional capital, including a conditional Tranche 2 loan. Given the mixed signals of growth alongside significant financial and operational risks, a 'hold' recommendation is appropriate, advising investors to monitor the company's progress on profitability, Nasdaq compliance, and resolution of legal and governmental challenges before making further investment decisions.

Keywords

bioelectronic technology, nVNS, gammaCore, Quell Fibromyalgia, Truvaga, TAC-STIM, neuromodulation, chronic pain, headache treatment, medical devices, FDA cleared, SEC filing, 10-Q, financial results, Nasdaq listing, patent litigation, government contracts, VA sales, capital raise, NeuroMetrix acquisition